242 related articles for article (PubMed ID: 37858962)
1. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence-based morphological fingerprinting of megakaryocytes: a new tool for assessing disease in MPN patients.
Sirinukunwattana K; Aberdeen A; Theissen H; Sousos N; Psaila B; Mead AJ; Turner GDH; Rees G; Rittscher J; Royston D
Blood Adv; 2020 Jul; 4(14):3284-3294. PubMed ID: 32706893
[TBL] [Abstract][Full Text] [Related]
3. Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry.
Ng WY; Erber WN; Grigg A; Dunne K; Perkins A; Forsyth C; Ross DM
Pathology; 2024 Feb; 56(1):75-80. PubMed ID: 38071156
[TBL] [Abstract][Full Text] [Related]
4. Tissue microarray technique is applicable to bone marrow biopsies of myeloproliferative neoplasms.
Limberger KA; Bogatyreva L; Todorova R; Herde B; Hauschke D; Pahl HL; Werner M; Aumann K
Histochem Cell Biol; 2017 Jan; 147(1):75-82. PubMed ID: 27544663
[TBL] [Abstract][Full Text] [Related]
5. Remodeling the Bone Marrow Microenvironment - A Proposal for Targeting Pro-inflammatory Contributors in MPN.
Jutzi JS; Mullally A
Front Immunol; 2020; 11():2093. PubMed ID: 32983162
[TBL] [Abstract][Full Text] [Related]
6. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
7. Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients.
Ryou H; Sirinukunwattana K; Aberdeen A; Grindstaff G; Stolz BJ; Byrne H; Harrington HA; Sousos N; Godfrey AL; Harrison CN; Psaila B; Mead AJ; Rees G; Turner GDH; Rittscher J; Royston D
Leukemia; 2023 Feb; 37(2):348-358. PubMed ID: 36470992
[TBL] [Abstract][Full Text] [Related]
8. [The unclassifiable myeloproliferative neoplasm--morphological, cytogenetic and clinical features].
Borovecki A; Skrtić A; Paro MM; Lasan R; Dominis M
Acta Med Croatica; 2011 Sep; 65 Suppl 1():31-6. PubMed ID: 23126027
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathogenesis of Myeloproliferative Neoplasms.
Rolles B; Mullally A
Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
[TBL] [Abstract][Full Text] [Related]
10. [Myelodysplastic/myeloproliferative neoplasm: a histopathological review].
Kayano H
Rinsho Ketsueki; 2018; 59(10):2084-2088. PubMed ID: 30305512
[TBL] [Abstract][Full Text] [Related]
11. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
[TBL] [Abstract][Full Text] [Related]
12. Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver.
Bonometti A; Borsani O; Rumi E; Ferretti VV; Dioli C; Lucato E; Paulli M; Boveri E
Cancer Med; 2023 Apr; 12(7):7815-7822. PubMed ID: 36524315
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms.
Malherbe JA; Fuller KA; Arshad A; Nangalia J; Romeo G; Hall SL; Meehan KS; Guo B; Howman R; Erber WN
J Clin Pathol; 2016 Feb; 69(2):155-63. PubMed ID: 26290261
[TBL] [Abstract][Full Text] [Related]
14. [Construction of a Mouse Model for Myeloproliferative Neoplasms and an Evaluation System].
Wang SJ; Yu XR; Zhang QG; Li YJ; Fu CL; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1113-1118. PubMed ID: 37551485
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow microenvironment of MPN cells.
Malara A; Di Buduo CA; Abbonante V; Balduini A
Int Rev Cell Mol Biol; 2021; 365():71-96. PubMed ID: 34756245
[TBL] [Abstract][Full Text] [Related]
16. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.
Wong WJ; Baltay M; Getz A; Fuhrman K; Aster JC; Hasserjian RP; Pozdnyakova O
PLoS One; 2019; 14(5):e0216810. PubMed ID: 31071164
[TBL] [Abstract][Full Text] [Related]
18. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
19. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
20. Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
Keski H
Blood Cells Mol Dis; 2020 May; 82():102420. PubMed ID: 32179412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
